A part of Merck

ALP10-KC | Apolipoprotein A-I, human (1mg) KC

ALP10-KC
Bulk packaging. Please inquire.  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information
      Description
      Catalogue NumberALP10-KC
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionApolipoprotein A-I, human (1mg) KC
      OverviewThis product is intended for use by IVD manufacturers.
      Contact customer service for assistance: oem.reagents@emdmillipore.com
      Alternate Names
      • ApoAI
      References
      Product Information
      PresentationLiquid in 10 mM NH4HCO3, pH 7.4. Non-sterile, no preservatives.
      Applications
      Key Applications
      • Positive Control
      Biological Information
      Concentration1.35 mg/mL
      Purity> 98%.

      High Density Lipoprotein (HDL) isolated by ultracentrifugation are delipidated. Apo A-I is purified by column chromatography in 6M urea (Schonfeld et al. 1977). Purity is determined by quantitative densitometric of SDS polyacrylamide gels (Laemlli 1970). Protein is determined by the Pierce BCA method (which was found to be comparable to the Lowry method) with BSA as the standard.

      MOLECULAR WEIGHT:
      28,000
      SourceNormal human plasma, fresh, non-frozen. Tested negative for HIV-1, HIV-2, HCV and HBc antibodies and HBsAg.
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.
      Gene Symbol
      • APOA1
      • ApoA-I
      • MGC117399
      • preproapolipoprotein
      • amyloidosis
      • Apo-AI
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P02647 # Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT).
      SIZE: 267 amino acids; 30778 Da
      SUBUNIT: Interacts with APOA1BP.
      SUBCELLULAR LOCATION: Secreted.
      TISSUE SPECIFICITY: Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
      PTM: Palmitoylated.
      DISEASE: SwissProt: P02647 # Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant. & Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I. & Defects in APOA1 are a cause of systemic non-neuropathic amyloidosis [MIM:105200]; also known as amyloidosis VIII or Ostertag-type amyloidosis. It is an autosomal dominant disorder characterized by generalized amyloid deposition.
      SIMILARITY: SwissProt: P02647 ## Belongs to the apolipoprotein A1/A4/E family.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain lyophilized material at < -20°C for up to six months. Maintain reconstituted Apo A-I at +4°C up to 4 weeks. Freezing solutions of apolipoproteins in the absence of denaturants may favor increased self-association or aggregation.
      Packaging Information
      Material SizeBulk packaging. Please inquire.
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Related Products & Applications

      Alternative Packsize

      Catalogue Number Description  
      ALP10 Apolipoprotein A-I, human Show Pricing & Availability

      Related Products By: Brand Facete

      Categories

      IVD/OEM Materials & Reagents > Bulk & Custom Antibodies > Primary Bulk Antibodies by Target > Lipoproteins
      Life Science Research > Proteins and Enzymes > Other Proteins